List of Excipients in Branded Drug CLARITIN CHEWABLE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	ANHYDROUS CITRIC ACID
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	ASPARTAME
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	FD&C BLUE NO. 1--ALUMINUM LAKE
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	MAGNESIUM STEARATE
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	MANNITOL
Bayer HealthCare LLC	CLARITIN CHEWABLE	loratadine	11523-4364	MENTHOL

Claritin Chewable Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Claritin Chewable is a mature, loratadine-based pediatric and family allergy product with limited core patent protection and meaningful room for excipient-led differentiation. The strongest opportunities are sugar reduction, improved taste masking, removal of allergen-sensitive excipients, faster disintegration, and lower-cost manufacturing. Product claims must remain within the FDA OTC pathway and cannot imply superior antihistamine efficacy without supporting clinical evidence.

What is Claritin Chewable and how is it regulated?

Claritin Chewable contains loratadine, a nonprescription second-generation antihistamine. The U.S. pediatric chewable product is generally marketed at 5 mg loratadine per tablet. The product is intended for children and adults according to age and dosing directions on the Drug Facts label. U.S. labeling identifies the product as a chewable tablet rather than an orally disintegrating tablet, which leaves room for formulation and sensory differentiation.[1]

FDA regulatory status

Loratadine is an established OTC active ingredient for allergy and hay fever indications. The FDA’s OTC framework permits products to be marketed under applicable monograph conditions or through an approved application, depending on the product’s regulatory history and formulation.[2]

Attribute	Claritin Chewable position
Active ingredient	Loratadine
Typical strength	5 mg chewable tablet
Therapeutic class	Second-generation H1 antihistamine
Primary use	Temporary relief of allergy symptoms
Dosage form	Chewable tablet
U.S. status	OTC product
Primary target	Pediatric and family allergy market
Biosimilar exposure	None
Generic/alternative exposure	High
Principal differentiation lever	Taste, excipient profile, convenience, brand trust

The product is not exposed to biosimilar competition because loratadine is a small molecule. Competitive pressure comes from generic loratadine chewables, orally disintegrating tablets, syrups, dissolvable products, and competing antihistamines such as cetirizine and fexofenadine.

What excipients are used in Claritin Chewable?

The U.S. product label identifies a conventional chewable-tablet excipient system. Depending on the specific presentation and market, the formulation may include mannitol, lactose, microcrystalline cellulose, corn starch, povidone, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, flavoring agents, sweeteners, and acids or pH-adjusting components.[1]

Because Claritin products are sold in multiple countries and package configurations, excipient composition must be checked against the exact National Drug Code, label revision, and jurisdiction. The relevant commercial assessment is the marketed formula, not the ingredient list for a similarly named product.

Functional role of the main excipient classes

Excipient class	Likely function	Commercial relevance
Mannitol	Bulking agent, cooling mouthfeel, sweetness	Supports sugar-free chewable formats
Lactose	Diluent and texture modifier	May create allergen, intolerance, and clean-label concerns
Microcrystalline cellulose	Compressibility and tablet structure	Supports direct compression and mechanical strength
Corn starch	Binder, disintegrant, filler	Low-cost conventional processing aid
Povidone	Binder	Helps tablet cohesion at low active loading
Sodium starch glycolate	Superdisintegrant	Supports rapid breakup after chewing or swallowing
Magnesium stearate	Lubricant	Controls ejection and manufacturing friction
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder handling
Flavor and sweetener system	Taste masking and acceptability	Primary consumer-facing differentiation lever

Loratadine has a low dose relative to the tablet mass. That makes excipients responsible for most of the tablet’s sensory performance, mouthfeel, hardness, friability, dissolution, and manufacturing economics.

How strong is the excipient patent estate for Claritin Chewable?

The core loratadine patent estate is expired in the United States. Claritin therefore does not retain meaningful exclusivity from the original active-ingredient patents. Product-specific formulation patents, if any remain listed or enforceable in a particular jurisdiction, must be assessed separately from the expired compound protection.

Patent strength assessment

Protection category	Current commercial value
Loratadine compound patents	Low; expired
Original Claritin formulation patents	Limited and generally mature
Chewable-tablet composition claims	Potentially available for new entrants, but narrow
Taste-masking claims	Moderate opportunity if technically specific
Particle-size or solid-state claims	Potentially useful but difficult to make broad
Manufacturing-process claims	Moderate value where they reduce cost or improve consistency
Brand and trade dress	High practical value for the incumbent
OTC regulatory positioning	Important but not exclusive
Pediatric flavor and sensory data	Commercial value, generally not blocking IP

A new excipient patent is unlikely to protect a broad “loratadine chewable” concept. A stronger filing would require a defined technical combination, such as a particular particle-size distribution, taste-masking polymer, compressed-flavor architecture, moisture-control system, or disintegration profile linked to measurable performance.

What patent claims could support a new product?

Potentially defensible claims could cover:

1. A loratadine chewable containing a defined mannitol and cellulose ratio.
2. A taste-masked loratadine particle coated with a pH-dependent or saliva-triggered polymer.
3. A low-water-activity tablet with specified hardness, friability, and dissolution limits.
4. A lactose-free and aspartame-free pediatric formulation.
5. A rapidly disintegrating chewable with a defined disintegration time and mouthfeel profile.
6. A manufacturing process that reduces sticking, segregation, or content-uniformity failures.
7. A dual-layer or microencapsulated tablet that separates bitterness from the initial saliva phase.

Generic composition claims based only on common excipients would face substantial obviousness risk. The patent position improves where the formulation solves a documented loratadine-specific problem, particularly bitterness, poor powder flow, tablet capping, moisture sensitivity, or unacceptable pediatric texture.

What is the Orange Book and Paragraph IV risk for Claritin Chewable?

Orange Book risk is limited by the age of the product and the expiration of the principal loratadine exclusivity. The commercial threat is generic substitution rather than a new Paragraph IV event against a meaningful active patent estate.

The FDA Orange Book remains the principal source for checking listed patents, approved strengths, dosage forms, therapeutic-equivalence codes, and discontinued presentations.[3] A generic applicant can pursue an ANDA where the reference product and regulatory pathway are suitable. Depending on the product’s regulatory status and applicable OTC rules, competitors may also rely on the OTC monograph pathway or market an equivalent product under other authorized routes.

Generic launch scenarios

Scenario	Probability	Market effect
Conventional generic 5 mg chewable	High	Price erosion and retail substitution
Sugar-free generic chewable	High	Direct competition with brand and store brands
Loratadine orally disintegrating tablet	Medium to high	Captures consumers seeking no-water dosing
Loratadine liquid or syrup	High	Competes for younger children
Premium taste-masked chewable	Medium	Supports retailer or private-label premium
Novel combination allergy product	Medium	Expands basket size but raises regulatory complexity

A Paragraph IV challenge would matter only if an unexpired, listed patent covered the relevant reference product and the applicant made a certified challenge. For a mature loratadine chewable, the practical barrier is more likely manufacturing scale, retailer access, consumer recognition, and formulation performance than patent litigation.

When does Claritin Chewable lose exclusivity?

Claritin’s active-ingredient exclusivity has already ended. Loratadine has been available in generic forms for years, and the U.S. market contains multiple generic and store-brand alternatives.

Exclusivity element	Status
Loratadine compound exclusivity	Expired
Original prescription-era market exclusivity	Expired
Pediatric chewable market protection	No meaningful compound-based barrier
FDA data exclusivity	Expired for the mature product
Trademark protection	Continues subject to renewal and use
Trade dress and packaging	Potentially enforceable, but narrower than patent rights
Formulation-specific new IP	Available only for newly developed improvements

The incumbent’s commercial protection now depends on brand equity, distribution, shelf placement, advertising, packaging, quality consistency, and consumer familiarity.

What formulation opportunities exist for a new Claritin Chewable competitor?

Sugar-free and low-sugar formulations

A sugar-free product using mannitol, xylitol, isomalt, erythritol, or combinations could target parents seeking reduced sugar exposure. Polyol systems require control of cooling sensation, hygroscopicity, gastrointestinal tolerance, and tablet hardness.

Mannitol is commercially attractive because it offers a relatively clean taste and cooling mouthfeel. Xylitol can improve sweetness and dental positioning but may increase moisture sensitivity and cost. Isomalt can provide good compressibility and lower hygroscopicity than some other polyols.

Aspartame-free and allergen-conscious products

If the marketed formula contains aspartame or lactose in a relevant presentation, an alternative product can target consumers avoiding phenylalanine sources or milk-derived excipients. The strongest positioning is factual:

• aspartame-free;
• lactose-free;
• gluten-free, where substantiated;
• artificial-color-free;
• vegan-compatible, where all materials support the claim.

Each claim requires supplier documentation, manufacturing controls, and label substantiation.

Improved taste masking

Loratadine is not an ideal pediatric active from a sensory perspective. A competitor can use:

• polymer-coated API particles;
• ion-exchange resin complexes;
• lipid or wax barriers;
• pH-controlled flavor release;
• layered tablet construction;
• high-intensity sweetener blends;
• fruit flavors with acid and cooling balance.

Taste masking should be tested in trained sensory panels and target-age acceptability studies. A strong commercial product needs low bitterness during chewing, limited aftertaste, and a texture that does not become chalky or sticky.

Faster disintegration and smaller tablets

Parents may prefer a smaller tablet that can be chewed without water. A reduced tablet size can be achieved through higher-density excipients, coated API particles, or a more efficient filler-binder system. The formulation must preserve content uniformity despite the low loratadine dose.

A “fast-melting” or “dissolves in the mouth” positioning would require careful regulatory classification. A chewable tablet should not be marketed as an orally disintegrating tablet unless it meets the applicable dosage-form and labeling expectations.

Moisture-resistant packaging

Chewable tablets are vulnerable to flavor loss, softening, sticking, and hardness changes. Commercial opportunities include:

• unit-dose blister packaging;
• high-barrier bottles;
• desiccant closures;
• child-resistant packaging with improved opening ergonomics;
• individually wrapped tablets for travel and school use.

Packaging can be more commercially important than a marginal excipient change because it affects shelf life, portability, and perceived quality.

How does Claritin Chewable compare with competing antihistamine products?

Product category	Active ingredient	Main advantage	Excipient opportunity
Loratadine chewable	Loratadine	Familiar, generally nonsedating positioning	Taste, sugar-free, small tablet
Cetirizine chewable	Cetirizine	Strong allergy symptom recognition	Reduced drowsiness messaging must be handled carefully
Fexofenadine chewable	Fexofenadine	Nonsedating brand positioning	Higher-dose tablet and taste management
Loratadine liquid	Loratadine	Flexible pediatric dosing	Preservatives, flavor, dosing accuracy
Orally disintegrating antihistamine	Varies	No-water convenience	Mouthfeel, packaging, moisture control

Claritin competes in a crowded category where efficacy differences are less important to many OTC shoppers than speed, sedation perceptions, age suitability, taste, price, and retailer availability.

Which companies are commercial competitors?

The competitive set includes Bayer’s Claritin brand, generic manufacturers, major retail private-label operators, and other branded antihistamine companies. Likely commercial competitors include:

• Perrigo;
• Teva;
• Viatris;
• CVS, Walgreens, Walmart, and other private-label suppliers;
• Haleon’s Zyrtec and related allergy brands;
• Opella’s Allegra and related products;
• regional OTC manufacturers and contract development and manufacturing organizations.

Private-label products can compete effectively because loratadine’s active ingredient is inexpensive and the key manufacturing requirements are established. A differentiated excipient system can support retailer exclusivity, but it must create a visible consumer benefit or a measurable cost advantage.

What manufacturing and IP barriers affect a new chewable?

The main barriers are technical rather than foundational patent barriers.

Manufacturing barriers

A low-dose chewable requires strong control of:

• API segregation;
• content uniformity;
• powder flow;
• tablet capping and lamination;
• lubricant overuse;
• flavor volatility;
• moisture uptake;
• coating uniformity;
• hardness and friability;
• microbial quality for flavored products.

Taste-masked API particles can increase manufacturing complexity and may impair dissolution if coating thickness is excessive. Polyol-heavy systems can create sticking and picking problems, especially under high humidity.

IP and freedom-to-operate barriers

Freedom-to-operate review should cover:

• active loratadine particle technology;
• taste-masking coatings;
• ion-exchange resin complexes;
• orally disintegrating or rapidly dispersible tablet architecture;
• flavor-release systems;
• compression tooling and manufacturing methods;
• packaging configurations;
• third-party excipient technology licenses.

A new entrant should avoid copying Claritin’s trade dress, color scheme, tablet shape, flavor identity, and packaging architecture. Trademark and trade-dress exposure can create launch risk even when patent barriers are absent.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve formulation technology than loratadine itself. Relevant partners include:

• excipient suppliers with co-processed direct-compression systems;
• taste-masking technology companies;
• pediatric sensory-testing providers;
• OTC contract manufacturers;
• private-label retailers;
• high-barrier packaging suppliers;
• regional consumer-health distributors.

The most attractive deal structure is likely a formulation or manufacturing license tied to a retailer-exclusive product, geographic rights, or a differentiated claim set. A license based solely on a standard loratadine chewable is unlikely to command significant value.

What is the revenue exposure and commercial upside?

The incumbent faces revenue erosion from low-cost generics, but the Claritin brand retains value through broad awareness and retailer presence. A new product can create commercial value in four areas:

1. Private-label substitution at lower cost.
2. Premium pediatric products with superior taste.
3. International markets with limited branded competition.
4. Line extensions using liquid, chewable, dissolvable, or multi-symptom formats.

The highest-probability opportunity is a low-cost, sugar-free, lactose-free chewable with a clearly improved flavor profile. The highest-margin opportunity is a premium pediatric product supported by proprietary taste masking, high-barrier packaging, and retailer or regional exclusivity.

Key Takeaways

• Claritin Chewable is a mature loratadine product with expired core active-ingredient exclusivity.
• Generic and private-label competition is structurally strong.
• Excipient strategy is the main route to differentiation.
• The best targets are taste masking, sugar reduction, lactose or aspartame removal, tablet-size reduction, and moisture protection.
• Broad formulation patents will be difficult to obtain; narrow, technically demonstrated claims are more defensible.
• The principal launch risks are sensory failure, low-dose content-uniformity problems, packaging instability, and trade-dress conflict.
• A retailer-focused, sugar-free pediatric chewable is the clearest commercial opportunity.

FAQs

Can a new loratadine chewable be patented?

Yes, but a broad loratadine chewable claim is unlikely to be strong. Patentability improves for a defined excipient ratio, taste-masking architecture, particle system, disintegration profile, or manufacturing process that produces unexpected performance.

Does Claritin Chewable have biosimilar risk?

No. Loratadine is a small-molecule drug. Competition comes from generics, OTC monograph products, private-label products, and competing antihistamines.

Is lactose-free Claritin Chewable commercially attractive?

Yes. A lactose-free formulation can address consumer preferences and simplify positioning for shoppers avoiding dairy-derived excipients. The product must maintain acceptable texture, sweetness, and tablet strength.

What is the best sweetener system for a pediatric loratadine chewable?

Mannitol combined with a high-intensity sweetener and a fruit flavor system is a practical starting point. Xylitol or isomalt can support alternative sensory and sugar-free profiles, but moisture, cooling sensation, cost, and gastrointestinal tolerance require optimization.

Can a competitor launch a generic Claritin Chewable without licensing Bayer?

Generally, a competitor does not need a license to Bayer’s expired loratadine compound rights. It must comply with applicable FDA requirements, avoid protected trademarks and trade dress, and clear any surviving formulation, process, packaging, or technology rights.

References

1. DailyMed. (n.d.). Claritin children’s chewables: Loratadine tablet, chewable, product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2007). Nonsterile semisolid dosage forms and chewable tablets: Guidance and regulatory considerations. U.S. Department of Health and Human Services.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.